nicorandil has been researched along with Atherogenesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gori, T | 1 |
| Araki, S; Izumiya, Y; Kaikita, K; Kojima, S; Matsubara, J; Nagayoshi, Y; Ogawa, H; Sakamoto, K; Sugiyama, S; Tsujita, K; Usuku, H | 1 |
1 review(s) available for nicorandil and Atherogenesis
| Article | Year |
|---|---|
Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis.
Topics: Animals; Atherosclerosis; Endothelium, Vascular; Humans; Metabolic Networks and Pathways; Nicorandil; Nitrates; Nitric Oxide; Nitric Oxide Donors | 2020 |
1 other study(ies) available for nicorandil and Atherogenesis
| Article | Year |
|---|---|
Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angina Pectoris; Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cardiovascular Agents; Cells, Cultured; Chi-Square Distribution; Coronary Artery Disease; Cytokines; Disease Models, Animal; Drug Administration Schedule; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endothelial Cells; Fibrosis; Humans; Inflammation Mediators; Japan; Lipids; Logistic Models; Macrophages; Male; Mice; Mice, Knockout; Middle Aged; Molecular Chaperones; Necrosis; Nicorandil; Odds Ratio; Retrospective Studies; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |